Tolna Vármegyei Balassa János Kórház

Verified siteinfo

Hungary Beri Balogh Adam Utca 5-7, 7100 Szekszard, Hungary

22 trials recruiting
Breast cancer · Non-small cell lung cancer · Atrial fibrillation
Adults and children

About Specializations

Tolna Vármegyei Balassa János Kórház in Szekszard, Hungary specialises in clinical trials of conditions such as Breast cancer, Non-small cell lung cancer, Atrial fibrillation, Breast cancer metastatic, and other specialisations. This site conducts important research.

Main research areas of the site

Oncology

The medical center is at the forefront of oncology research, focusing on innovative treatments for various types of cancer. The center's commitment to advancing cancer therapy is exemplified by its exploration of novel drug delivery methods and targeted therapies.

Recurrent or Metastatic HER2 Negative Breast Cancer
Targeted Cancer Therapies
Innovative Drug Delivery Systems

Through its research, the center aims to improve progression-free survival rates and enhance the quality of life for patients with challenging cancer diagnoses.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Beri Balogh Adam Utca 5-77100 SzekszardHungary

Open in maps ↗

Recruiting now: 22 trials
Conditions studied: 43
Partner status: Verified site

More sites in Szekszard Hungary

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

59 clinical trials

Non-small cell lung cancer+1

Recruiting

Phase III Randomized Study of Rilvegostomig vs. Pembrolizumab with Platinum-based Chemotherapy in PD-L1 Expressing Metastatic Squamous NSCLC

Registered drugNo placebo

Phase III Randomized Study of Rilvegostomig vs. Pembrolizumab with Platinum-based Chemotherapy in PD-L1 Expressing Metastatic Squamous NSCLC

Registered drugNo placebo

Hungary

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:AstraZeneca AB

Contact Research Centre

Cardiovascular disorder+1

Recruiting

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational

Hungary

Participants:18–64 years · 65+ years
Substances:Zilebesiran
Sponsor:Alnylam Pharmaceuticals Inc.

Contact Research Centre

Cardiovascular disorder+2

Recruiting

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug

Hungary

Participants:18–64 years · 65+ years
Substances:BI 690517
Sponsor:Boehringer Ingelheim Espana S.A.

Contact Research Centre

Non-small cell lung cancer

Recruiting

Study comparing rilvegostomig plus chemotherapy versus pembrolizumab plus chemotherapy for first-line treatment in patients with metastatic non-squamous lung cancer with PD-L1 expression

Registered drugNo placebo